Empagliflozin in Heart Failure with a Preserved Ejection Fraction
Top Cited Papers
- 14 October 2021
- journal article
- research article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 385 (16), 1451-1461
- https://doi.org/10.1056/nejmoa2107038
Abstract
Sodium–glucose cotransporter 2 inhibitors reduce the risk of hospitalization for heart failure in patients with heart failure and a reduced ejection fraction, but their effects in patients with heart failure and a preserved ejection fraction are uncertain. In this double-blind trial, we randomly assigned 5988 patients with class II–IV heart failure and an ejection fraction of more than 40% to receive empagliflozin (10 mg once daily) or placebo, in addition to usual therapy. The primary outcome was a composite of cardiovascular death or hospitalization for heart failure. Over a median of 26.2 months, a primary outcome event occurred in 415 of 2997 patients (13.8%) in the empagliflozin group and in 511 of 2991 patients (17.1%) in the placebo group (hazard ratio, 0.79; 95% confidence interval [CI], 0.69 to 0.90; P<0.001). This effect was mainly related to a lower risk of hospitalization for heart failure in the empagliflozin group. The effects of empagliflozin appeared consistent in patients with or without diabetes. The total number of hospitalizations for heart failure was lower in the empagliflozin group than in the placebo group (407 with empagliflozin and 541 with placebo; hazard ratio, 0.73; 95% CI, 0.61 to 0.88; P<0.001). Uncomplicated genital and urinary tract infections and hypotension were reported more frequently with empagliflozin. Empagliflozin reduced the combined risk of cardiovascular death or hospitalization for heart failure in patients with heart failure and a preserved ejection fraction, regardless of the presence or absence of diabetes. (Funded by Boehringer Ingelheim and Eli Lilly; EMPEROR-Preserved ClinicalTrials.gov number, NCT03057951).Funding Information
- Boehringer Ingelheim
- Eli Lilly and Company
This publication has 16 references indexed in Scilit:
- Redefining Heart Failure With a Reduced Ejection FractionJAMA, 2019
- Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection FractionThe New England Journal of Medicine, 2019
- Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes MellitusCirculation, 2019
- Effects of Canagliflozin on Heart Failure Outcomes Associated With Preserved and Reduced Ejection Fraction in Type 2 Diabetes MellitusCirculation, 2019
- SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trialsThe Lancet, 2018
- Heart failure with mid‐range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrumEuropean Journal of Heart Failure, 2018
- Mid-range left ventricular ejection fraction: Clinical profile and cause of death in ambulatory patients with chronic heart failureInternational Journal of Cardiology, 2017
- Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fractionEuropean Heart Journal, 2015
- Spironolactone for Heart Failure with Preserved Ejection FractionThe New England Journal of Medicine, 2014
- Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved TrialThe Lancet, 2003